Major U.S. stock indices declined on Wednesday as technology stocks underperformed ahead of Nvidia’s (NVDA) highly anticipated earnings report, released after the market closed.

The S&P 500 lost 0.6 percent, while the Dow ended the midweek session 0.4 percent lower. The downtrend in technology stocks contributed to the Nasdaq’s 1.1 percent loss.

Shares of server and data center technology company Super Micro Computer (SMCI) plunged 19.0%, the weakest performer of any S&P 500 stock. The company announced Wednesday that it would delay the filing of its annual Form 10K with the Securities and Exchange Commission (SEC). Supermicro’s decision to delay the filing came a day after activist investment firm Hindenburg Research accused the company of accounting anomalies and disclosed a short position in the stock.

Bath & Body Works (BBWI) shares fell 7.0% after the personal care and beauty products retailer cut its full-year sales forecast. The company said consumers remain cautious about expensive purchases due to ongoing inflation, leading to weaker demand for the company’s products such as perfumes and scented candles.

The impact of inflation on consumer spending also weighed on shares of JM Smucker (SJM), which fell 5% after the food maker missed quarterly sales estimates and cut its full-year forecast. The CEO of the company behind Jif peanut butter and the jam of the same name said “selective” spending behavior was particularly affecting sales of sweet baked goods and weighing on the company’s Hostess brand.

Shares of Insulet (PODD), maker of devices used to treat diabetes, posted the biggest daily gains in the S&P 500, rising 6.2%. Wednesday’s strong performance continued an uptrend from the previous session after Insulet received approval from the Food and Drug Administration (FDA) for its Omnipod 5 wearable delivery system for use by patients with type 2 diabetes.

Bio-Rad Laboratories (BIO) shares gained 2.9% after Nephron Research upgraded the stock to a buy rating. The clinical diagnostic testing provider is benefiting from a strong pipeline in its digital PCR business as well as growing demand for quality control, blood typing and diabetes products.

Tyson Foods (TSN) shares rose 2.8% on Wednesday, hitting a new 52-week high. Earlier this week, Zacks Equities Research highlighted Tyson as an attractive momentum stock, citing its strong recent performance and rising earnings expectations.